Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc is positioned favorably due to its focus on developing therapies for orphan pulmonary and fibrosis indications, with two Phase 2-ready clinical assets that address unmet medical needs. The company's clinical trials have shown promising results, particularly with LTI-03, which demonstrated increased sRAGE levels, indicating potential efficacy. Overall, the stock presents a favorable risk-reward opportunity, especially if the company successfully extends its cash runway, supported by a best-in-class pipeline targeting significant market opportunities currently lacking in effective treatment options.

Bears say

Rein Therapeutics Inc's stock has experienced a significant decline of 50% year to date in 2025, which starkly contrasts with the 3.5% increase observed in the XBI index. This deterioration in stock performance is largely attributed to the company's decision to pause enrollments in the U.S. for its clinical trials, creating heightened investor uncertainty regarding future progress and revenue potential. Furthermore, concerning biomarker data indicates that lower sRAGE levels are linked to poor survival outcomes in patients with Idiopathic Pulmonary Fibrosis, raising questions about the efficacy and viability of the company's therapeutic candidates in a competitive market.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.